News | Radiopharmaceuticals and Tracers | May 09, 2018

Theranostic radiohybrid (rh)PSMA pharmaceuticals have potential utility in both imaging and therapy of prostate cancer

May 9, 2018 — Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in radiopharmaceuticals and radiopharmaceutical technologies. Under the terms of the agreement, Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of prostate specific membrane antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer imaging, together with an exclusive option to explore therapeutic applications.

Blue Earth Diagnostics will drive development of a lead 18F rhPSMA imaging compound and collaborate with Scintomics to identify optimized therapeutic candidates for future development. The company said acquisition of the rights to this advanced technology provides strong synergies with Axumin (fluciclovine F-18), Blue Earth Diagnostics’ approved and commercially available positron emission tomography/computed tomography (PET/CT) imaging agent for use in patients with a rising PSA after prior prostate cancer treatment.

Scintomics’ theranostic “radiohybrid” technology allows for the efficient labelling of PSMA-targeted agents with imaging radioisotopes, such as 18F, or therapeutic radioisotopes such as 177Lu. This could potentially be used either as a prostate cancer imaging agent or as a therapeutic agent. If approved, these compounds offer the possibility of precision medicine for men with prostate cancer.

“As evidenced by its recent inclusion in the National Comprehensive Cancer Network guidelines, 18F-fluciclovine has become established as a standard-of-care PET imaging agent in the United States for men with recurrent prostate cancer,” said Judd Moul, M.D., professor of surgery and director, Duke Prostate Center, Duke University Medical Center, Durham, N.C. “It is clear that PSMA-targeted PET imaging agents will play an important role in the future management of prostate cancer patients. However, there is a wide array of these agents in development, and some have more promising attributes than others. Optimally, a PSMA-targeted diagnostic agent for routine clinical use should be labeled with the radioisotope 18F for its durability and possess favorable clinical attributes that facilitate broad applicability and utility in men with prostate cancer.”

For more information: www.blueearthdiagnostics.com

 


Related Content

News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | ASTRO

June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...

Time June 21, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 18, 2024
arrow
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
arrow
Subscribe Now